BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) stock has reached a new 52-week high, climbing to $9.02, as investors rally ...
RESEARCH TRIANGLE PARK, N.C. - BioCryst Pharmaceuticals , Inc. (NASDAQ:BCRX), a biotechnology company with impressive revenue growth of nearly 30% over the last twelve months, has announced that ...
Pharmaceuticals announced that Infarmed in Portugal has recommended ORLADEYO for the routine prevention of recurrent attacks of ...
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Infarmed in Portugal has recommended ORLADEYO® ...
KBC Group NV grew its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 80.1% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 10,198 shares ...
Pharmaceuticals announced that the company will present five abstracts featuring new clinical and real-world outcomes with ...
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter 2024 financial ...